Unknown

Dataset Information

TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial.


ABSTRACT:

Rational

While a variety of registered therapies exist for Cutaneous T Cell Lymphoma, no such therapy is available for Cutaneous B Cell Therapy. In this context we performed a phase II, open label, multicenter, non-comparative study to evaluate the efficacy and safety of repeated intra-lesional administrations of TG1042 (adenovirus-interferon-γ) in patients with relapsing primary cutaneous B-cell lymphomas (CBCL).

Method

Thirteen patients have been enrolled and received intralesional injections of TG1042 containing 5×10(10) viral particles into up to six lesions simultaneously. Injections were performed on days 1, 8 and 15 of each of four consecutive 28 day cycles.

Results

Eleven (85%) out of 13 enrolled patients showed an objective response after injections of TG1042

SUBMITTER: Dreno B 

PROVIDER: S-EPMC3933342 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature